On July 7, 2025, Oppenheimer analyst Suraj Kalia initiated coverage on Pulse Biosciences (PLSE, Financial) with an "Outperform" rating, signaling a positive outlook for the company's stock performance. The stock is projected to reach a target price of $22.00 USD.
Pulse Biosciences (PLSE, Financial) is gaining attention with this recent coverage initiation, as investors look to Suraj Kalia's analysis for insights. The lack of a prior rating or target price suggests that this is the first assessment by the analyst on the company.
The announcement, focused on the anticipated growth trajectory of PLSE, comes at a time when investors are closely monitoring market shifts and seeking potential investment opportunities. With the "Outperform" rating, Oppenheimer expresses confidence in the company’s future performance relative to the broader market.
